Frédéric Fiteni

1.3k total citations
41 papers, 611 citations indexed

About

Frédéric Fiteni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Frédéric Fiteni has authored 41 papers receiving a total of 611 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Frédéric Fiteni's work include Cancer survivorship and care (7 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Frédéric Fiteni is often cited by papers focused on Cancer survivorship and care (7 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Frédéric Fiteni collaborates with scholars based in France, Belgium and Netherlands. Frédéric Fiteni's co-authors include Franck Bonnetain, Virginie Westeel, Christophe Borg, Amélie Anota, Xavier Pivot, Déwi Vernerey, Sophie Paget‐Bailly, Caroline Mollévi, Zeinab Hamidou and Stéfano Kim and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Respiratory Journal.

In The Last Decade

Frédéric Fiteni

37 papers receiving 600 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frédéric Fiteni France 14 346 266 133 108 85 41 611
Anna Ceribelli Italy 15 577 1.7× 449 1.7× 112 0.8× 66 0.6× 132 1.6× 35 1.0k
Annette Wigertz Sweden 16 335 1.0× 216 0.8× 166 1.2× 81 0.8× 237 2.8× 19 1.0k
Niels Neymark Belgium 11 352 1.0× 397 1.5× 112 0.8× 92 0.9× 56 0.7× 21 640
Yasin Folkvaljon Sweden 17 213 0.6× 595 2.2× 247 1.9× 70 0.6× 65 0.8× 37 947
Diana T. Chingos United States 8 278 0.8× 117 0.4× 60 0.5× 77 0.7× 110 1.3× 8 516
Jaclyn Beca Canada 15 284 0.8× 204 0.8× 61 0.5× 251 2.3× 101 1.2× 58 691
Dorothy Romanus United States 16 507 1.5× 132 0.5× 138 1.0× 114 1.1× 39 0.5× 49 881
Antonella Venturino Italy 14 533 1.5× 279 1.0× 133 1.0× 91 0.8× 140 1.6× 57 953
N.J. Latino Israel 10 295 0.9× 185 0.7× 47 0.4× 301 2.8× 101 1.2× 17 654
Ronald Kodama Canada 14 189 0.5× 661 2.5× 279 2.1× 54 0.5× 57 0.7× 37 1.1k

Countries citing papers authored by Frédéric Fiteni

Since Specialization
Citations

This map shows the geographic impact of Frédéric Fiteni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Fiteni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Fiteni more than expected).

Fields of papers citing papers by Frédéric Fiteni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Fiteni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Fiteni. The network helps show where Frédéric Fiteni may publish in the future.

Co-authorship network of co-authors of Frédéric Fiteni

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Fiteni. A scholar is included among the top collaborators of Frédéric Fiteni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Fiteni. Frédéric Fiteni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bidard, François‐Clément, Frédérique Berger, Mónica Arnedos, et al.. (2024). Clinical utility of ctDNA as a tool to detect triple-negative breast cancer relapses: The CUPCAKE trial.. Journal of Clinical Oncology. 42(16_suppl). TPS1139–TPS1139. 1 indexed citations
2.
Fiteni, Frédéric, et al.. (2023). Combinaisons d’inhibiteurs de points de contrôle immunitaires en oncologie : état de l’art et perspectives. Bulletin du Cancer. 110(7-8). 790–801. 1 indexed citations
3.
Leenhardt, Fanny, Frédéric Fiteni, Séverine Guiu, et al.. (2022). Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects. Pharmaceutics. 14(4). 841–841. 9 indexed citations
4.
5.
Fiteni, Frédéric, et al.. (2019). Health-related quality of life as an endpoint in oncology phase I trials: a systematic review. BMC Cancer. 19(1). 361–361. 27 indexed citations
6.
Cottone, Francesco, Fabio Efficace, Célia Touraine, et al.. (2019). Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review. Quality of Life Research. 29(4). 867–878. 14 indexed citations
7.
Fiteni, Frédéric, Zohair Selmani, Antoine Baumann, et al.. (2018). Enterocolitis in Patients with Cancer Treated with Docetaxel. Anticancer Research. 38(4). 2443–2446. 5 indexed citations
8.
9.
Fiteni, Frédéric, et al.. (2018). Clinical Relevance of Routine Monitoring of Patient-reported Outcomes Versus Clinician-reported Outcomes in Oncology. In Vivo. 33(1). 17–21. 11 indexed citations
10.
11.
Fiteni, Frédéric, Amélie Anota, Virginie Westeel, & Franck Bonnetain. (2016). Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review. BMC Cancer. 16(1). 122–122. 31 indexed citations
12.
Fiteni, Frédéric, Amélie Anota, Franck Bonnetain, et al.. (2016). Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. European Respiratory Journal. 48(3). 861–872. 14 indexed citations
13.
Kim, Stéfano, Sophie Paget‐Bailly, Mathieu Messager, et al.. (2016). Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma. European Journal of Surgical Oncology. 43(1). 218–225. 11 indexed citations
14.
Fiteni, Frédéric, Amélie Anota, Virginie Westeel, & Franck Bonnetain. (2015). La qualité de vie relative à la santé dans les essais cliniques de phase III en oncologie : de l’administration du questionnaire à l’analyse statistique. Bulletin du Cancer. 102(4). 360–366. 5 indexed citations
15.
Fiteni, Frédéric, Déwi Vernerey, Franck Bonnetain, et al.. (2015). Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. European Journal of Cancer. 52. 120–128. 35 indexed citations
16.
Fiteni, Frédéric, Amélie Anota, Déwi Vernerey, et al.. (2015). Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology. Expert Review of Anticancer Therapy. 15(8). 885–891. 13 indexed citations
17.
Dobi, Erion, Astrid Pozet, Hamadi Almotlak, et al.. (2015). Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study. Molecular and Clinical Oncology. 3(6). 1208–1212. 13 indexed citations
18.
Fiteni, Frédéric, Virginie Westeel, Xavier Pivot, et al.. (2014). Endpoints in cancer clinical trials. Journal of Visceral Surgery. 151(1). 17–22. 81 indexed citations
19.
20.
Fiteni, Frédéric, Cristian Villanueva, Fernando Bazán, et al.. (2013). Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: Impact of institutions. The Breast. 23(2). 165–169. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Ceribelli Breakdown of academic impact, for papers by Annette Wigertz Breakdown of academic impact, for papers by Niels Neymark Breakdown of academic impact, for papers by Yasin Folkvaljon Breakdown of academic impact, for papers by Diana T. Chingos Breakdown of academic impact, for papers by Jaclyn Beca Breakdown of academic impact, for papers by Dorothy Romanus Breakdown of academic impact, for papers by Antonella Venturino Breakdown of academic impact, for papers by N.J. Latino Breakdown of academic impact, for papers by Ronald Kodama
Rankless by CCL
2026